Despite a mountain of claims that the blood cleaning product GranuFlo (a dry acid used in the operation of dialysis procedures) causes increased risk of cardiac abnormalities, Fresenius Medical, makers of the product, insist that plaintiffs have no merit in bringing suit.

Mounting evidence and studies have shown that the drug has been shown to increase likelihood of death from cardiac arrest by up to six times. In addition to such devastating effects, GranuFlo has also been said to increase the risks of heart attack and stroke in patients being treated with the drug. Still, with all the evidence and studies weighing against them, Fresenius stands by its assertions that plaintiffs’ claims are meritless and there is no proof that GranuFlo is an unreasonably dangerous drug for which the company failed to adequately warn about. Fresenius believes not only did they not fail to warn, but that such risks do not even exist. Unfortunately for Fresenius the endless proof to the contrary does not look good for their defense.

Excess Amount of Bicarbonate in GranuFlo

One such piece of evidence comes from an internal memo from November 4, 2011 that included warnings regarding an excess amount of bicarbonate in GranuFlo which increased the risk for patients to have sudden cardiac arrest leading to death during dialysis. According to the urgent memo, 941 patients in 2010 alone suffered cardiac arrest inside Fresenius clinics.

Fresenius Medical Care is currently under investigation by the FDA who is trying to conclude why it is that the company did not share its deadly findings with patients or the centers that dispensed dialysis treatment using GranuFlo. Though Fresenius continues to assert the lack of merit in Plaintiffs’ cases, attorneys representing several wronged patients believe in their case and claims, especially that the facts and studies are strong and will prove that the company failed to warn about the increased risks of GranuFlo.